← RHYTHM PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Available to Common Stockholders, Basic | ($29.1m) |
($37.6m)
-29.26%
|
($74.1m)
-97.07%
|
($140.7m)
-90.01%
|
($134.0m)
+4.78%
|
— | — | — | ($264.6m) |
($201.9m)
+23.68%
|
— | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($25.9m) | ($33.7m) | ($74.1m) | ($140.7m) | ($134.0m) | ($69.6m) | ($181.1m) | ($184.7m) | ($260.6m) | ($196.5m) | — | |
| Depreciation, Depletion and Amortization | $144k | $223k | $442k | $834k | $690k | $816k | $896k | $903k | $710k | $500k | $1.1m | |
| Amortization of Intangible Assets | — | — | — | — | — | $342k | $774k | $855k | — | — | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | — | — | — | — | $0 | — | |
| Share-based Payment Arrangement, Noncash Expense | $1.2m | $2.3m | $6.4m | $11.9m | $17.5m | $20.8m | $19.8m | $32.6m | $39.7m | $66.8m | $87.2m | |
| Share-based Payment Arrangement, Expense | — | — | — | — | — | — | $19.8m | $32.6m | $39.7m | $66.8m | $87.2m | |
| Equity Method Investment, Realized Gain (Loss) on Disposal | — | — | — | — | — | — | ($1.0m) | — | — | — | — | |
| Nonoperating Income (Expense) | $33k | ($1.3m) | $4.4m | $5.3m | $2.6m | $100.4m | ($2.0m) | $243k | $5.2m | ($4.0m) | — | |
| Other Nonoperating Income (Expense) | — | — | — | — | — | — | ($790k) | $190k | $2.2m | $1.3m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | $5.2m | $8.6m | $3.6m | $7.6m | ($14.8m) | |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | $2.8m | $5.7m | $10.1m | $7.5m | ($12.8m) | |
| Net Cash Provided by (Used in) Operating Activities | ($23.2m) |
($29.5m)
-26.88%
|
($62.1m)
-110.64%
|
($122.8m)
-97.81%
|
($122.0m)
+0.63%
|
($146.0m)
-19.69%
|
($173.4m)
-18.78%
|
($136.2m)
+21.49%
|
($113.9m)
+16.36%
|
($115.7m)
-1.58%
|
($105.3m)
+8.93%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $1.1m | $133k | $722k | $3.4m | $214k | $434k | $281k | $47k | $0 | $953k | ($953k) | |
| Cash, Cash Equivalents, and Short-term Investments | $10.5m | $148.1m | $252.1m | $292.5m | $172.8m | $294.9m | $333.3m | $275.8m | $320.6m | $388.9m | — | |
| Marketable Securities, Unrealized Gain (Loss) | — | — | — | — | $49k | ($50k) | — | $366k | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | ($5.1m) | ($110.0m) | ($87.1m) | ($28.0m) | $158.5m | ($62.2m) | $28.0m | ($5.7m) | ($48.2m) | ($137.2m) | ($144.9m) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | — | — | — | — | — | — | — | $7.4m | $12.9m | $19.9m | — | |
| Proceeds from Issuance of Long-term Debt | — | — | — | — | — | — | $72.3m | $24.4m | — | $0 | — | |
| Proceeds from Issuance of Common Stock | — | $125.7m | $162.9m | $161.4m | — | $161.7m | $131.1m | $48.9m | $39.1m | $34.0m | $188.7m | |
| Net Cash Provided by (Used in) Financing Activities | — | $167.2m |
$164.7m
-1.50%
|
$163.5m
-0.74%
|
$2.0m
-98.77%
|
$166.5m
+8186.76%
|
$213.8m
+28.44%
|
$74.4m
-65.22%
|
$191.2m
+157.16%
|
$218.0m
+13.97%
|
$179.8m
-17.51%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | ($28.3m) | $27.7m | $15.5m | $12.8m | $38.6m | ($41.7m) | $68.4m | ($67.6m) | $29.2m | ($34.8m) | $65.6m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | ($28.3m) | $27.7m | $49.9m | $62.7m | $101.3m | ($41.7m) | $68.4m | ($67.6m) | $29.2m | ($34.8m) | $65.6m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | $700k | $1.8m | $1.6m | $1.5m | $4.1m | $9.8m | $7.5m | $16.0m | $13.6m | — | |
| Additional Financial Items | ||||||||||||
| Derivative, Gain (Loss) on Derivative, Net | — | — | — | — | — | — | — | — | $8.9m | $0 | — | |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | — | $564k | $346k | $497k | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $20.6m | $20.6m | — | |
| Investment Income, Interest | $33k | $566k | $4.4m | $5.3m | $2.6m | $447k | — | — | — | — | — | |
| Operating Expenses | $25.9m | $32.4m | $78.4m | $146.0m | $136.6m | — | — | — | — | — | — | |
| Operating Lease, Expense | — | — | — | $629k | $551k | $551k | $551k | $551k | — | — | — | |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | — | $0 | $0 | $3.2m | $23.6m | $77.4m | — | — | — |